在铁灭过程中,RSL3通过不同的机制促进PARP1的亡功能
Dejian Chen1,2, Fei Xie3, Yimei Mo2
1Wenzhou Key Laboratory of Cancer Pathogenesis and Translation, Key Laboratory of Laboratory Medicine, School of Laboratory Medicine and Life Sciences, Ministry of Education, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Cellular & molecular biology letters
|October 2, 2025
概括
铁亡激活剂RSL3通过Poly (ADP-ribose) 聚合酶1 (PARP1) 调节诱导了亡,提供了新的治疗途径. 这种机制即使在耐PARP抑制剂的癌症中也是有效的.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞死亡途径 细胞死亡途径
背景情况:
- 铁灭激活剂RSL3主要针对谷氨过氧化酶4 (GPX4).
- 在ferroptosis期间诱导apoptosis的RSL3的作用尚未完全理解.
- 在DNA损伤反应和亡中,PARP1 (Poly(ADP-ribose) 聚合酶1 (PARP1) 是至关重要的.
研究的目的:
- 为了阐明RSL3诱导的亡机理在ferroptosis.
- 为了研究RSL3.3对PARP1的调节.
- 评估RSL3在PARP抑制剂耐药癌症中的治疗潜力.
主要方法:
- 用RSL3治疗癌细胞以诱导亡.
- 通过RT-qPCR和Western blot分析PARP1调节蛋白.
- 使用MeRIP-qPCR对PARP1的N6-methyladenosine (m6A) 修饰的评估.
- 建立一种耐PARP抑制剂 (PARPi) 的小鼠异种移植模型.
主要成果:
- RSL3通过酶依赖的PARP1裂变和通过减少全长PARP1的DNA损伤依赖的亡诱导了亡.
- RSL3 抑制了 METTL3 中介的 m6A 修改,抑制了 PARP1 的翻译.
- 在PARPi耐药模型中,RSL3显示出亲亡效应,并抑制瘤生长.
结论:
- 通过PARP1调节,RSL3调节了铁灭亡-灭亡交叉声.
- RSL3对瘤发生有治疗潜力,特别是在抗PARPi的癌症中.
相关概念视频
Necrosis
6.3K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
6.3K
Overview of Cell Death
9.4K
Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
9.4K
Regulation of the Unfolded Protein Response
2.9K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.9K
The Unfolded Protein Response
6.2K
The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
6.2K
The Intrinsic Apoptotic Pathway
8.3K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.3K
Long-patch Base Excision Repair
7.9K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.9K
